## **Reed M Hawkins**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1730295/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 <sup>+</sup> and CD4 <sup>+</sup> CD19-specific chimeric antigen receptor–modified T cells. Science Translational Medicine, 2016, 8, 355ra116.	12.4	832
2	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019, 133, 1652-1663.	1.4	277
3	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood, 2019, 133, 1876-1887.	1.4	230
4	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood, 2020, 135, 1650-1660.	1.4	222
5	Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nature Communications, 2020, 11, 219.	12.8	167
6	Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature, 2022, 606, 791-796.	27.8	162
7	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood, 2019, 134, 636-640.	1.4	127
8	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood, 2021, 137, 323-335.	1.4	111
9	Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 1415-1415.	1.4	6
10	Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells Journal of Clinical Oncology, 2018, 36, 7005-7005.	1.6	2
11	Clonal Kinetics and Single Cell Transcriptional Profiling of Adoptively Transferred CD19 CAR-T Cells.	1.4	1